PF-04691502 is a small molecule inhibitor of the phosphatidylinositol 3-kinase (PI3K) pathway, which plays a crucial role in regulating cell growth and survival. It is currently being investigated for its potential therapeutic use in various types of cancer.
Chemical name: N-(4-((2-(2-chloro-4-(1-methylpiperidine-4-yl)phenylamino)-pyrimidin-4-yl)amino)phenyl)acetamide Molecular formula: C24H29ClN6O Formula weight: 451.98 g/mol CAS No: 1013101-36-4
Top ten keywords from Google and Synonyms:
Health benefits of this product: PF-04691502 has shown promising results in preclinical studies for its potential use in treating various types of cancers, such as solid tumors and non-small cell lung cancer. Its ability to inhibit the PI3K pathway, which is involved in cell growth and survival, may lead to the suppression of tumor growth and the induction of apoptosis, or programmed cell death.
Potential effects: Studies have demonstrated that PF-04691502 has potential therapeutic effects in various types of cancer. It has also been shown to sensitize cancer cells to other therapies, such as radiation therapy and chemotherapy.
Product mechanism: PF-04691502 works by inhibiting the activity of PI3K, a key enzyme in the PI3K/AKT/mTOR signaling pathway. This pathway is critical for regulating cell growth and proliferation, and its dysregulation can lead to uncontrolled cell growth and tumor formation. By inhibiting PI3K, PF-04691502 can block downstream activation of key signaling molecules such as AKT, which are essential for cell survival and growth. This leads to apoptosis, or programmed cell death, and the suppression of cancer cell growth.
Safety: As with any medication, safety is a concern when using PF-04691502. Studies have shown that it is generally well-tolerated and has a good safety profile. However, like other PI3K inhibitors, it can cause side effects such as diarrhea, nausea, vomiting, and fatigue. It is important to consult with a healthcare provider before using PF-04691502 and to closely monitor any potential side effects.
Side effects: Some of the common side effects of PF-04691502 include gastrointestinal symptoms such as diarrhea, nausea, vomiting, and abdominal pain. Other potential side effects include fatigue, headache, and rash. In rare cases, PF-04691502 can cause serious side effects such as liver toxicity and lung inflammation, so close monitoring is recommended.
Dosing information: PF-04691502 is typically administered orally as a capsule. The optimal dose and duration of treatment will vary depending on the individual patient and the type of disease being treated. It is important to follow dosing instructions carefully and to consult with a healthcare provider before beginning treatment with PF-04691502.
Conclusion: PF-04691502 is a promising small molecule inhibitor that has demonstrated potential in treating various types of cancer by inhibiting the activity of the PI3K pathway, a key regulator of cell growth and proliferation. Although it has a good safety profile, potential side effects must be closely monitored. Further research is needed to fully explore the therapeutic potential of PF-04691502 and its applications in treating various diseases.
